☰

Martha D. Port, Ph.D. - Publications

Affiliations: 
2008 University of Washington, Seattle, Seattle, WA 
Area:
Signal transduction
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

3/10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Port MD, Laszlo GS, Nathanson NM. Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cells. Journal of Neurochemistry. 106: 1941-51. PMID 18624908 DOI: 10.1111/J.1471-4159.2008.05535.X  0.534
2008 Port MD, Laszlo GS, Nathanson NM. Transregulation of leukemia inhibitory factor receptor expression and function by growth factors in neuroblastoma cells (Journal of Neurochemistry (2008) 106, (1941-1951)) Journal of Neurochemistry. 107: 1470. DOI: 10.1111/J.1471-4159.2008.05635.X  0.497
2007 Port MD, Gibson RM, Nathanson NM. Differential stimulation-induced receptor localization in lipid rafts for interleukin-6 family cytokines signaling through the gp130/leukemia inhibitory factor receptor complex. Journal of Neurochemistry. 101: 782-93. PMID 17448148 DOI: 10.1111/J.1471-4159.2007.04471.X  0.477
Low-probability matches (unlikely to be authored by this person)
2005 Forsthoefel NR, Cutler K, Port MD, Yamamoto T, Vernon DM. PIRLs: a novel class of plant intracellular leucine-rich repeat proteins. Plant & Cell Physiology. 46: 913-22. PMID 15809230 DOI: 10.1093/pcp/pci097  0.137
2020 Ford JH, Kurth T, Starling AJ, Ayer DW, Wietecha LA, Port MD, Rettiganti M, Ruff DD. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Headache. 60: 2304-2319. PMID 33249580 DOI: 10.1111/head.14013  0.026
2023 Lipton RB, Buse DC, Sandoe CH, Ford JH, Hand AL, Jedynak JP, Port MD, Detke HC. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache. PMID 36797223 DOI: 10.1111/head.14460  0.024
2020 Stauffer VL, Turner I, Kemmer P, Kielbasa W, Day K, Port M, Quinlan T, Camporeale A. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. The Journal of Headache and Pain. 21: 79. PMID 32576229 DOI: 10.1186/S10194-020-01148-9  0.018
2022 Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache. 62: 198-207. PMID 35076090 DOI: 10.1111/head.14257  0.018
2019 Loo LS, Ailani J, Schim J, Baygani S, Hundemer HP, Port M, Krege JH. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain. 20: 84. PMID 31340760 DOI: 10.1186/s10194-019-1032-x  0.01
2021 Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, Stroud C, Tockhorn-Heidenreich A, Detke HC. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Advances in Therapy. PMID 34542830 DOI: 10.1007/s12325-021-01911-7  0.01
Hide low-probability matches.